Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...
Home / News / Pearce IP Blog
ALL BLOGS BY
Kate Legge
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...
Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the...
The Full Federal Court overturns AI inventorship in Australia
An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by...
Patent litigation in Australia just got a little cheaper
The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news...
Pharmacia’s Dynastat patent valid, imminent patent expiry no reason to avoid injunction
Introduction Pharmacia LLC and Pfizer Australia Pty Ltd (together, Pharmacia) have partially succeeded at first...
PTE alert: Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs)...
Comments period on draft new National Medicines Policy extended – now closing on 2 March
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft...
No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP...
To waive or not to waive: that is the question
IP waivers alone are nowhere near enough to increase COVID-19 vaccine access for developing countries, but US support...
The COVID-19 pandemic prioritises an Australian medical products’ manufacturing road map
Background In October 2020, the Australian Government announced a $1.5 billion investment in a Modern Manufacturing...